Summary
Kelonia Therapeutics presented updated ASCO 2026 data supporting continued advancement of its in vivo CAR-T platform, which engineers CAR-T cells directly inside patients using targeted lentiviral delivery technology.
What Happened
Kelonia shared updated clinical progress from its in vivo CAR-T platform at ASCO 2026. Rather than harvesting T cells and manufacturing CAR-T products externally, the company aims to generate CAR-T cells directly inside the patient.
Deep Analysis
In vivo CAR-T is one of the most important long-term objectives in cell therapy. If successful, it could eliminate manufacturing cost, vein-to-vein delays, scalability constraints, and access limitations. The platform has the potential to transform CAR-T from a manufacturing service into a drug-like therapeutic modality.
Company / Product Background
Kelonia Therapeutics is developing targeted lentiviral delivery technologies designed to engineer immune cells directly inside the body.
Signal Extraction
– In vivo CAR-T remains a major platform opportunity
– Potential elimination of manufacturing bottlenecks
– Direct challenge to autologous CAR-T models
– Broad future applicability across oncology and immune diseases
Insilens Take
– Opportunity: Scalable cell therapy architecture
– Risk: Delivery specificity and safety
– Watch Signal: Durable responses and expansion cohorts
– Action: Monitor competitive positioning versus ex vivo CAR-T
